Skip to main content

The one-day virtual nanoDDS symposium welcomed more than 800 registered participants, the largest turnout in the past 18 years, said Alexander “Sasha” Kabanov, director of the UNC Center for Nanotechnology in Drug Delivery, which supported the event. Nearly 400 people in various time zones across the world attended nanoDDS live. Other registrants who could not attend because of time differences of the live meeting will receive access to the symposium lecture recordings.

This year’s symposium featured topics of cancer immunotherapy; tumor delivery; nanoformulation characterization; promoting diversity; research funding; and vaccines and therapeutics for COVID-19.

Among the plenary speakers were Robert Langer, Ph.D., of the Massachusetts Institute for Technology;  Joseph M. DeSimone, Ph.D. of the Stanford University; and Ralph Baric, Ph.D. of the UNC Gillings School of Global Public Health.

The most recent advances on COVID-19 vaccine and therapeutics were discussed by leaders from industry, including: Kimberly Hassett, Ph.D., a Senior Scientist, Formulation Science, at Moderna Therapeutics, MA; and Tomas Cihlar, Ph.D., a Vice President of Virology at Gilead Sciences, CA.

The highlights of the symposium were the two “power hours” – round table discussions on diversity and equity, and funding in nanomedicine research. One of the panelists during the diversity power hour Christine Allen, Ph.D., a Professor of Pharmacy and Associate Vice-President and Vice-Provost, Strategic Initiatives at the University of Toronto, said: “It meant so much to me to be part of this session and I really appreciated everyone sharing so openly.”

Elizabeth Wayne, Ph.D., Assistant Professor of Chemical Engineering and Biomedical Engineering at Carnegie Mellon University, who also spoke on the panel adds, “I am honored to have shared this moment with all of you. Being able to discuss our contributions and what we would like to develop in our field was beautiful and powerful.” Prior to her current appointment, Wayne was the first Postdoctoral Fellow in the NIH-funded “UNC Cancer Nanotechnology T32 Training Program,” led by Kabanov.

The two-day Carolina Nanoformulation Workshop that preceded nanoDDS featured presentations on cancer immunotherapy, development of COVID-19 vaccines, nanomedicines pharmacokinetics, manufacturing, characterization and clinical translation. The workshop featured lectures from experts in industry, the US Nanotechnology Characterization Laboratory and UNC-Chapel.

The workshop brings together scientists from industry, government and academia to discuss key matters of translating nanomedicine technologies to practical use to improve human health. The workshop provides ample time for discussion and brainstorming and includes graduate students and postdocs.

This is the fourth event organized by the UNC Center for Nanotechnology in Drug Delivery since 2016.

Because of the pandemic, this year both the Carolina Nanoformulation Workshop and nanoDDS were combined together and held as virtual events.

“It turned out to be a huge success. It has been very important to continue on despite COVID-19 and bring the newest advances in our science to hundreds of participants across the world. We have very positive feedback from many participants,” Kabanov said.

To read the full UNC Eshelman School of Pharmacy article, please click here.

Comments are closed.